The use of diazoxide in the management of spontaneous hypoglycemia in patients with ESRD
Although diabetes remains the number one cause of renal failure nationwide, spontaneous hypoglycemia in patients with CKD has also been described in the absence of exogenous insulin or any other diabetes treatment. Decreased renal gluconeogenesis and impaired renal insulin clearance are underlying mechanisms of hypoglycemia in individuals with ESRD. Diazoxide was originally approved as an anti-hypertensive medication, but also is known to bind ATP-sensitive K channels in the beta cells of the pancreas, ultimately leading to inhibition of insulin release. We detail six cases of ESRD-associated hypoglycemia which responded to treatment with diazoxide therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
CEN case reports - 9(2020), 3 vom: 09. Aug., Seite 271-277 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mesmar, Bayan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Case Reports |
|---|
| Anmerkungen: |
Date Completed 31.08.2021 Date Revised 31.08.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s13730-020-00471-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM308597923 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308597923 | ||
| 003 | DE-627 | ||
| 005 | 20231225132053.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13730-020-00471-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1028.xml |
| 035 | |a (DE-627)NLM308597923 | ||
| 035 | |a (NLM)32274651 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mesmar, Bayan |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The use of diazoxide in the management of spontaneous hypoglycemia in patients with ESRD |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.08.2021 | ||
| 500 | |a Date Revised 31.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Although diabetes remains the number one cause of renal failure nationwide, spontaneous hypoglycemia in patients with CKD has also been described in the absence of exogenous insulin or any other diabetes treatment. Decreased renal gluconeogenesis and impaired renal insulin clearance are underlying mechanisms of hypoglycemia in individuals with ESRD. Diazoxide was originally approved as an anti-hypertensive medication, but also is known to bind ATP-sensitive K channels in the beta cells of the pancreas, ultimately leading to inhibition of insulin release. We detail six cases of ESRD-associated hypoglycemia which responded to treatment with diazoxide therapy | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Diazoxide | |
| 650 | 4 | |a ESRD | |
| 650 | 4 | |a Hypoglycaemia | |
| 650 | 7 | |a Vasodilator Agents |2 NLM | |
| 650 | 7 | |a Diazoxide |2 NLM | |
| 650 | 7 | |a O5CB12L4FN |2 NLM | |
| 700 | 1 | |a Kristan, Megan |e verfasserin |4 aut | |
| 700 | 1 | |a Satyarengga, Medha |e verfasserin |4 aut | |
| 700 | 1 | |a Lamos, Elizabeth M |e verfasserin |4 aut | |
| 700 | 1 | |a Malek, Rana |e verfasserin |4 aut | |
| 700 | 1 | |a Munir, Kashif M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t CEN case reports |d 2012 |g 9(2020), 3 vom: 09. Aug., Seite 271-277 |w (DE-627)NLM250223260 |x 2192-4449 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2020 |g number:3 |g day:09 |g month:08 |g pages:271-277 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s13730-020-00471-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2020 |e 3 |b 09 |c 08 |h 271-277 | ||